Skip to main content
Erschienen in: Supportive Care in Cancer 7/2011

01.07.2011 | Original Article

Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?

verfasst von: Marianne Paesmans, Jean Klastersky, Johan Maertens, Aspasia Georgala, Frédérique Muanza, Mickael Aoun, Augustin Ferrant, Bernardo Rapoport, Ken Rolston, Lieveke Ameye

Erschienen in: Supportive Care in Cancer | Ausgabe 7/2011

Einloggen, um Zugang zu erhalten

Abstract

Background

Febrile neutropenic cancer patients represent a heterogeneous population with a limited proportion at risk of serious medical complications. The Multinational Association for Supportive Care in Cancer (MASCC) score has been developed and validated for identifying low-risk patients at the onset of febrile neutropenia. Since bacteremia, although not documented at baseline, is a predictor of pejorative outcome, the purpose of this study was to investigate the possible interaction between the MASCC score and bacteremic status and to assess whether, assuming that bacteremic status could be predicted at onset of febrile neutropenia, adding bacteremia as a covariate in a risk model would improve the accuracy of low-risk patients identification.

Methods

Two consecutive multicentric observational studies were carried out from 1994 till 2005 involving 2,142 febrile neutropenic patients. The study data bases were retrospectively used for the present analysis.

Results

A predictive value was found for the MASCC score in all strata obtained by stratification for the bacteremic status with odds ratios for successful outcome being, in patients with a score ≥21, respectively, 6.06 (95%CI: 4.51–8.15), 3.42 (95%CI: 1.95–5.98), and 6.04 (95%CI: 3.01–12.09) in patients without bacteremia, gram-positive bacteremia, and gram-negative bacteremia. No interaction between the MASCC score and the bacteremic status was present. A clinical prediction rule integrating the MASCC score and the bacteremic status was not helpful in improving the identification of low-risk patients. This rule may then be used in a general population of patients with febrile neutropenia without having concerns for a lower predictive value in bacteremic patients.

Conclusions

Our results suggest that the knowledge, provided we could find a model to predict it at fever onset, of a bacteremic etiology of the fever would be of little additional value to the MASCC score when attempting to identify low-risk patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Klastersky J, Ameye L, Maertens J et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(suppl 1):S51–S59PubMedCrossRef Klastersky J, Ameye L, Maertens J et al (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents 30(suppl 1):S51–S59PubMedCrossRef
2.
Zurück zum Zitat Klastersky J, Zinner SH, Calandra T et al (1988) Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24(suppl 1):S35–S45PubMed Klastersky J, Zinner SH, Calandra T et al (1988) Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials. Eur J Cancer Clin Oncol 24(suppl 1):S35–S45PubMed
3.
Zurück zum Zitat Viscoli C, Bruzzi P, Castagnola E et al (1994) Factors associated with bacteremia in febrile, granulocytopenic cancer patients. Eur J Cancer 30:430–437CrossRef Viscoli C, Bruzzi P, Castagnola E et al (1994) Factors associated with bacteremia in febrile, granulocytopenic cancer patients. Eur J Cancer 30:430–437CrossRef
4.
Zurück zum Zitat Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT (2006) Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect 12:217–223PubMedCrossRef Norgaard M, Larsson H, Pedersen G, Schonheyder HC, Sorensen HT (2006) Risk of bacteraemia and mortality in patients with haematological malignancies. Clin Microbiol Infect 12:217–223PubMedCrossRef
5.
Zurück zum Zitat Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed Talcott JA, Siegel RD, Finberg R, Goldman L (1992) Risk assessment in cancer patients with fever and neutropenia: a prospective, two-center validation of a prediction rule. J Clin Oncol 10:316–322PubMed
6.
Zurück zum Zitat Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed Klastersky J, Paesmans M, Rubenstein EB et al (2000) The Multinational Association for Supportive Care in Cancer risk index: a multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 18:3038–3051PubMed
7.
Zurück zum Zitat Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef Uys A, Rapoport BL, Anderson R (2004) Febrile neutropenia: a prospective study to validate the Multinational Association of Supportive Care of Cancer (MASCC) risk-index score. Support Care Cancer 12:555–560PubMedCrossRef
8.
Zurück zum Zitat Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef Klastersky J, Paesmans M, Georgala A et al (2006) Outpatient oral antibiotics for febrile neutropenic cancer patients using a score predictive for complications. J Clin Oncol 24:4129–4134PubMedCrossRef
9.
Zurück zum Zitat Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef Hughes WT, Armstrong D, Bodey GP et al (2002) 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 34:730–751PubMedCrossRef
10.
Zurück zum Zitat DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef DeLong ER, DeLong DM, Clarke-Pearson DL (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845PubMedCrossRef
11.
Zurück zum Zitat Kern WV, Heiss M, Steinbach G (2001) Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 32:832–835PubMedCrossRef Kern WV, Heiss M, Steinbach G (2001) Prediction of gram-negative bacteremia in patients with cancer and febrile neutropenia by means of interleukin-8 levels in serum: targeting empirical monotherapy versus combination therapy. Clin Infect Dis 32:832–835PubMedCrossRef
12.
Zurück zum Zitat Massaro KS, Costa SF, Leone C, Chamone DA (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137PubMedCrossRef Massaro KS, Costa SF, Leone C, Chamone DA (2007) Procalcitonin (PCT) and C-reactive protein (CRP) as severe systemic infection markers in febrile neutropenic adults. BMC Infect Dis 7:137PubMedCrossRef
13.
Zurück zum Zitat Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care 16:475–483CrossRef Uys A, Rapoport BL, Fickl H, Meyer PW, Anderson R (2007) Prediction of outcome in cancer patients with febrile neutropenia: comparison of the Multinational Association of Supportive Care in Cancer risk-index score with procalcitonin, C-reactive protein, serum amyloid A, and interleukins-1beta, -6, -8 and -10. Eur J Cancer Care 16:475–483CrossRef
14.
Zurück zum Zitat Elting LS, Rubenstein EB, Rolston KVI, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259PubMedCrossRef Elting LS, Rubenstein EB, Rolston KVI, Bodey GP (1997) Outcomes of bacteremia in patients with cancer and neutropenia: observations from two decades of epidemiological and clinical trials. Clin Infect Dis 25:247–259PubMedCrossRef
15.
Zurück zum Zitat Freifeld A, Marchigiani D, Walsh T et al (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311PubMedCrossRef Freifeld A, Marchigiani D, Walsh T et al (1999) A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy. N Engl J Med 341:305–311PubMedCrossRef
16.
Zurück zum Zitat Kern WV, Cometta A, de Rock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312–318PubMedCrossRef Kern WV, Cometta A, de Rock R et al (1999) Oral versus intravenous empirical antimicrobial therapy for fever in patients with granulocytopenia who are receiving cancer chemotherapy. N Engl J Med 341:312–318PubMedCrossRef
Metadaten
Titel
Predicting febrile neutropenic patients at low risk using the MASCC score: does bacteremia matter?
verfasst von
Marianne Paesmans
Jean Klastersky
Johan Maertens
Aspasia Georgala
Frédérique Muanza
Mickael Aoun
Augustin Ferrant
Bernardo Rapoport
Ken Rolston
Lieveke Ameye
Publikationsdatum
01.07.2011
Verlag
Springer-Verlag
Erschienen in
Supportive Care in Cancer / Ausgabe 7/2011
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-010-0925-7

Weitere Artikel der Ausgabe 7/2011

Supportive Care in Cancer 7/2011 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.